CAMP4 Therapeutics (CAMP) vs ProQR Therapeutics N.V. (PRQR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CAMP4 Therapeutics (CAMP) has outperformed ProQR Therapeutics N.V. (PRQR) over the past year, gaining 4.5% versus a loss of 28.2%. CAMP4 Therapeutics is the larger company by market cap ($232.2 million vs $221.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAMP | PRQR |
|---|---|---|
| Share price | $3.70 | $1.57 |
| Market cap | $232.19M | $221.56M |
| 1-day change | -3.65% | -3.68% |
| YTD return | -39.64% | -19.31% |
| 1-year return | +4.52% | -28.19% |
| 5-year return | — | -79.31% |
| EPS (TTM) | $-2.32 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.75 | $3.10 |
| 52-week low | $2.86 | $1.33 |
| Distance from 52-week high | -52.26% | -49.35% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +185.68% | +395.54% |
| Average volume | 279.32K | 796.41K |
| Shares outstanding | 62.75M | 141.12M |
| Employees | 48 | 186 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CAMP has outperformed PRQR by 32.7 percentage points over the past year.
About CAMP4 Therapeutics
CAMP stock →Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About ProQR Therapeutics N.V.
PRQR stock →ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs.
Health Care · Biotechnology: Pharmaceutical Preparations · 186 employees
CAMP vs PRQR FAQ
Which is bigger, CAMP4 Therapeutics or ProQR Therapeutics N.V.?
CAMP4 Therapeutics (CAMP) is larger, with a market capitalization of $232.19M compared with $221.56M for ProQR Therapeutics N.V. (PRQR).
Which stock has performed better over the past year, CAMP or PRQR?
CAMP returned +4.52% over the past 12 months, compared with -28.19% for PRQR (price return, excluding dividends). Past performance does not predict future results.
Are CAMP4 Therapeutics and ProQR Therapeutics N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.